Dtsch Med Wochenschr 2015; 140(04): 245-249
DOI: 10.1055/s-0041-100518
Dossier
Akutes Nierenversagen
© Georg Thieme Verlag KG Stuttgart · New York

Diagnostik und Pathophysiologie der akuten Nierenschädigung / des akuten Nierenversagens – Prävention möglich?

Diagnosis and pathophysiology of acute renal failure – is prevention possible?
Julius J. Schmidt
1   Medizinische Hochschule Hannover
,
Gernot Beutel
1   Medizinische Hochschule Hannover
,
Jan T. Kielstein
1   Medizinische Hochschule Hannover
› Author Affiliations
Further Information

Publication History

Publication Date:
19 February 2015 (online)

Zusammenfassung

Die akute Schädigung der Niere ist ein zunehmendes Problem in der ambulanten uns stationären Therapie von Patienten, insbesondere im Bereich der Intensivmedizin. Eine neue Definition und neue Biomarker sollen zu einer frühzeitigen Identifizierung von Risikopatienten und/oder Patienten mit bereits erfolgter Nierenschädigung führen, um ein Versagen der Nieren - also die Notwendigkeit einer Nierenersatztherapie zu reduzieren. Eine spezifische Therapie gibt es derzeit nicht, dennoch ist eine konsequente Vermeidung von Einflussfaktoren die die Niere schädigen, von nephrotoxischen Medikamenten bis zur protrahierten Hypotension, essentieller Bestandteil der Versorgung dieser Patienten. Einer der wichtigsten Faktoren zur Prävention und erfolgreichen Therapie ist das Vorhandensein klinisch-nephrologischer Expertise, die jedoch immer seltener anzutreffen ist.

Abstract

Acute kidney injury (AKI) in critically ill patients is on a dramatic rise. The same holds true for community acquired AKI. Two main mechanisms are responsible for this increase: the rising prevalence of chronic kidney disease and the progress in diagnostic and therapeutic procedures pushing the limits of impossible. Several new biomarkers have not only helped to identify patients at risk for AKI and diagnosing AKI within hours after the insult, they also helped improve our pathophysiological understanding of AKI. The increase in AKI and new diagnostic markers of it is currently not matched by an increase in prophylactic or therapeutic interventions. It is quite the opposite. For decades we have seen spectacular effects of new drugs and interventions in the preclinical setting, always followed by a miserable failure at the bedside. It seems that one non-pharmacological intervention, i. e. the human resource of being educated in nephrology might be of importance not only for those suffering from AKI in the intensive care unit but also for those surviving it. This comes to no surprise if one considers acute and chronic kidney diseases not as separate entities but rather as closely interconnected.

 
  • Literaturverzeichnis

  • 1 Mehta RL, Kellum JA, Shah SV et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11: R31
  • 2 Moeller C, Kohling H. Artificial kidney; a survey and personal experience. Klin Wochenschr 1956; 34: 569-577
  • 3 Friedrich JO, Adhikari N, Herridge MS et al. Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med 2005; 142: 510-524
  • 4 Bove T, Zangrillo A, Guarracino F et al. Effect of Fenoldopam on Use of Renal Replacement Therapy Among Patients With Acute Kidney Injury After Cardiac Surgery: A Randomized Clinical Trial. JAMA 2014; 312: 2244-2253
  • 5 Thomas ME, Blaine C, Dawnay A et al. The definition of acute kidney injury and its use in practice. Kidney international 2015; 87: 62-73
  • 6 Chertow GM, Burdick E, Honour M et al. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. Journal of the American Society of Nephrology : JASN 2005; 16: 3365-3370
  • 7 Murray PT, Mehta RL, Shaw A et al. Potential use of biomarkers in acute kidney injury: report and summary of recommendations from the 10 th Acute Dialysis Quality Initiative consensus conference. Kidney int 2014; 85: 513-521
  • 8 Haase M, Devarajan P, Haase-Fielitz A et al. The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury: a multicenter pooled analysis of prospective studies. J Am Coll Cardiol 2011; 57: 1752-1761
  • 9 Sabbisetti VS, Waikar SS, Antoine DJ et al. Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes. JASN 2014; 25: 2177-2186
  • 10 Lorenzen JM, Kielstein JT, Hafer C et al. Circulating miR-210 predicts survival in critically ill patients with acute kidney injury. CJASN 2011; 6: 1540-1546
  • 11 Bihorac A, Chawla LS, Shaw AD et al. Validation of cell-cycle arrest biomarkers for acute kidney injury using clinical adjudication. Am J Respir Crit Care Med 2014; 189: 932-939
  • 12 Coca SG, Garg AX, Thiessen-Philbrook H et al. Urinary biomarkers of AKI and mortality 3 years after cardiac surgery. JASN 2014; 25: 1063-1071
  • 13 Coca SG, Garg AX, Swaminathan M et al. Preoperative angiotensin-converting enzyme inhibitors and angiotensin receptor blocker use and acute kidney injury in patients undergoing cardiac surgery. Nephrol Dial Transplant 2013; 28: 2787-2799
  • 14 Alge JL, Arthur JM. Biomarkers of AKI: A Review of Mechanistic Relevance and Potential Therapeutic Implications. Clin J Am Soc Nephrol 2015; 10: 147-155
  • 15 Ejaz AA, Kambhampati G, Ejaz NI et al. Post-operative serum uric acid and acute kidney injury. J Nephrol 2012; 25: 497-505
  • 16 Huang TM, Wu VC, Young GH et al. Preoperative proteinuria predicts adverse renal outcomes after coronary artery bypass grafting. J Am Soc Nephrol 2011; 22: 156-163
  • 17 Bagshaw SM, Haase M, Haase-Fielitz A et al. A prospective evaluation of urine microscopy in septic and non-septic acute kidney injury. Nephrol Dial Transplant 27: 582-588
  • 18 Prowle JR, Kirwan CJ, Bellomo R. Fluid management for the prevention and attenuation of acute kidney injury. Nat Rev Nephrol 2014; 10: 37-47
  • 19 Grams ME, Estrella MM, Coresh J et al. Fluid balance, diuretic use, and mortality in acute kidney injury. CJASN 2011; 6: 966-973
  • 20 McDonald Jr RH, Goldberg LI, McNay JL et al. Effect of Dopamine in Man: Augmentation of Sodium Excretion, Glomerular Filtration Rate, and Renal Plasma Flow. J Clin Invest 1964; 43: 1116-1124
  • 21 Bellomo R, Chapman M, Finfer S et al. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 2000; 356: 2139-2143
  • 22 Ho KM, Sheridan DJ. Meta-analysis of frusemide to prevent or treat acute renal failure. BMJ 2006; 333: 420
  • 23 Inda-Filho AJ, Caixeta A, Manggini M et al. Do intravenous N-acetylcysteine and sodium bicarbonate prevent high osmolal contrast-induced acute kidney injury? A randomized controlled trial. PloS one 2014; 9: e107602
  • 24 Palevsky PM, Liu KD, Brophy PD et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury. Am J Kidney Dis 2013; 61: 649-672
  • 25 Allen SJ. Fluid therapy and outcome: balance is best. J Extra Corpor Technol 2014; 46: 28-32
  • 26 Nadeem A, Salahuddin N, ElHazmi A et al. Chloride-liberal fluids are associated with acute kidney injury after liver transplantation. Crit Care 2014; 18: 625
  • 27 Druml W. The renal failure patient. World Rev Nutr Diet 2013; 105: 126-135
  • 28 Schmidt JJ, Hafer C, Spielmann J et al. Removal characteristics and total dialysate content of glutamine and other amino acids in critically ill patients with acute kidney injury undergoing extended dialysis. Nephron Clin Pract 2014; 126: 62-66
  • 29 Hanrahan TP, Harlow G, Hutchinson J et al. Vancomycin-associated nephrotoxicity in the critically ill: a retrospective multivariate regression analysis. Crit Care 2014; 42: 2527-2536
  • 30 Khan NA, Susa D, van den Berg JW et al. Amelioration of renal ischaemia-reperfusion injury by synthetic oligopeptides related to human chorionic gonadotropin. Nephrol Dial Transplant 2009; 24: 2701-2708
  • 31 Peters E, Heemskerk S, Masereeuw R et al. Alkaline phosphatase: a possible treatment for sepsis-associated acute kidney injury in critically ill patients. Am J Kidney Dis 2014; 63: 1038-1048
  • 32 Whitaker RM, Wills LP, Stallons LJ et al. cGMP-selective phosphodiesterase inhibitors stimulate mitochondrial biogenesis and promote recovery from acute kidney injury. J Pharmacol Exp Ther 2013; 347: 626-634
  • 33 Selby NM, Crowley L, Fluck RJ et al. Use of electronic results reporting to diagnose and monitor AKI in hospitalized patients. CJASN 2012; 7: 533-540
  • 34 Balasubramanian G, Al-Aly Z, Moiz A et al. Early nephrologist involvement in hospital-acquired acute kidney injury: a pilot study. Am J Kidney Dis : the official journal of the National Kidney Foundation 2011; 57: 228-234
  • 35 Berns JS, Rosner MH. Onco-nephrology: what the nephrologist needs to know about cancer and the kidney. Clin J Am Soc Nephrol 2012; 7: 1691